Switching from semaglutide to tirzepatide?

If weight loss slowed on semaglutide and you wonder whether tirzepatide could help you lose more, the head-to-head result favors tirzepatide on average, about 20% versus about 14% at 72 weeks NEJM SURMOUNT-5 trial. You start tirzepatide low and raise the dose step by step, without taking the two together, and you track appetite, stomach tolerance, weight trend and blood sugar with your prescriber.

Could switching help you lose more weight?

In SURMOUNT-5, adults with obesity without diabetes took the highest dose they tolerated of either drug for 72 weeks. Average weight change was 20.2% lower with tirzepatide and 13.7% lower with semaglutide NEJM SURMOUNT-5 trial. Half the tirzepatide group lost 20% or more, compared with about one quarter of the semaglutide group Frontiers review of SURMOUNT-5. Those are group averages, so your result could land higher or lower.

Direction matters when you switch. Comment on the trial noted that people who do well on tirzepatide and then move to semaglutide will likely regain weight Healio SURMOUNT-5 coverage. A move back to semaglutide does not hold a tirzepatide loss in place.

What dose of tirzepatide equals semaglutide?

Doctors do not trade milligrams one for one. You stop semaglutide and start tirzepatide at a low dose, then raise it step by step until you reach a dose that curbs appetite with side effects you can live with. That stepwise start is called titration. Wegovy, for example, starts at 0.25 mg weekly and builds to 2.4 mg Pharmaceutical Journal switch guidance.

You do not overlap them to bridge the gap. The Wegovy label says not to use it with other products that contain semaglutide or with other drugs that act on the same gut hormone pathway FDA Wegovy label. Your prescriber sets how long to pause between the last semaglutide shot and the first tirzepatide shot.

What should you watch after you switch?

Expect the first weeks to tell you more about tolerance than about weight. Note nausea, vomiting, constipation or diarrhea, how hungry you feel between meals, and which dose you tolerated. Weigh under the same conditions and look at the trend across 4 to 12 weeks, not day to day shifts.

If you have type 2 diabetes, also track blood sugar and A1c, which reflects average blood sugar over about 3 months, with your prescriber. In a small 3-month chart review of 15 patients who switched from semaglutide 1.0 mg to tirzepatide, A1c fell by 0.7 on average only in the 5 patients who reached 10 mg, while weight showed a downward trend that did not reach statistical significance PubMed switch study. The size and length limit what you can take from it, and the head-to-head trial above did not include people with diabetes.

Bring three points to your prescriber and to the HOD quiz. The pause you used between drugs, the titration pace that fits your stomach history, and the weight and blood sugar pattern that would prompt a dose hold or change.